ABVC Biopharma Inc is not a strong buy at the moment for a beginner, long-term investor. The stock shows bearish technical indicators, lacks positive trading trends, and has no recent news or significant catalysts. While the financial performance has improved year-over-year, the company remains unprofitable, and there is no strong indication of immediate growth or momentum to justify a buy decision.

Technical Analysis

The stock is in a bearish trend with MACD below 0 and negatively expanding, RSI at 7.456 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The price is below key support levels, with the next support at 1.19.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Revenue increased by 104.47% YoY in Q3 2025, and gross margin improved slightly to 100%.

Neutral/Negative Catalysts

No recent news, no significant hedge fund or insider trading activity, no recent congress trading data, and the company remains unprofitable with a net income of -1,246,513 in Q3 2025.

Financial Performance

In Q3 2025, revenue increased to $795,950 (up 104.47% YoY), net income improved to -$1,246,513 (up 215.76% YoY), EPS increased to -0.05 (up 66.67% YoY), and gross margin slightly improved to 100%. However, the company remains unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast ABVC stock price to rise

Buy

Hold

Sell

Current: 1.310

Low

Averages

High